Answers are grounded in this paper and cite their sources.
Retrospective study compares response rates in hepatocellular carcinoma, suggesting radioembolization is more effective.
Background: Drug-eluting bead transarterial chemoembolization (DEB-TACE) and yttrium-90 ( 90 Y) radioembolization are approved therapies to treat hepatocellular carcinoma (HCC). Several randomized controlled trials and propensity score-matched studies (PSM) have been conducted to compare these 2 treatments; many utilized 90 Y standard dosimetry (<200 Gy), which produced inferior outcomes compared with modern-day 90 Y personalized dosimetry, which yields tumor doses exceeding 205 Gy. Purpose: This study utilized PSM between DEB-TACE and 90 Y with personalized dosimetry to compare treatment and patient outcomes in Barcelona Clinic Liver Cancer (BCLC) A–B HCC. Methods: This retrospective study included 258 patients with unresectable BCLC A–B stage HCC treated with DEB-TACE or 90 Y as the initial treatment approach from 2015 to 2024. PSM was performed ( 90 Y:DEB-TACE), matching for tumor burden and alpha-fetoprotein levels at diagnosis. The primary endpoint was target response rate with secondary endpoints of overall response, target retreatment rate (TTR), target and overall time-to-progression (TTP), and overall survival (OS). Results: Overall, 90 Y achieved significantly higher target complete (CR) and objective response (OR) rates compared with DEB-TACE (71% vs. 33% and 88% vs. 58%), respectively. In multifocal disease, target CR rates were higher following 90 Y (68% vs. 13%). 90 Y also yielded a longer duration of CR with a 1-year target retreatment rate of 12% compared with 40% with DEB-TACE. This translated into a longer target TPP ( p =0.030) with 90 Y, although overall TPP and OS were similar between treatment modalities. In multifocal disease, 90 Y generated superior response rates as well as target ( p =0.007) and overall TTP ( p =0.015). Conclusions: 90 Y with personalized dosimetry achieved higher response rates and extended the duration of complete responses compared with DEB-TACE. 90 Y was also more effective at treating multifocal disease.
No takes yet. Share an insight, caveat, or question.
Núñez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: